Callan Capital LLC Takes $281,000 Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Callan Capital LLC acquired a new stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,361 shares of the company's stock, valued at approximately $281,000.

A number of other hedge funds have also modified their holdings of the company. Envestnet Asset Management Inc. boosted its stake in shares of Genmab A/S by 1.7% in the first quarter. Envestnet Asset Management Inc. now owns 736,326 shares of the company's stock worth $14,417,000 after buying an additional 12,545 shares during the last quarter. DAVENPORT & Co LLC boosted its stake in shares of Genmab A/S by 21.1% in the first quarter. DAVENPORT & Co LLC now owns 31,679 shares of the company's stock worth $620,000 after buying an additional 5,529 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its stake in shares of Genmab A/S by 20.5% in the first quarter. Oppenheimer Asset Management Inc. now owns 249,468 shares of the company's stock worth $4,885,000 after buying an additional 42,361 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of Genmab A/S by 169.9% in the first quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock worth $145,000 after buying an additional 4,666 shares during the last quarter. Finally, QRG Capital Management Inc. boosted its stake in shares of Genmab A/S by 213.7% in the first quarter. QRG Capital Management Inc. now owns 74,847 shares of the company's stock worth $1,465,000 after buying an additional 50,990 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB traded down $0.46 during midday trading on Friday, hitting $21.40. The company had a trading volume of 1,247,549 shares, compared to its average volume of 1,253,561. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $28.56. The stock has a market cap of $13.73 billion, a price-to-earnings ratio of 12.16, a price-to-earnings-growth ratio of 6.51 and a beta of 0.94. The business's 50-day simple moving average is $21.04 and its 200-day simple moving average is $20.75.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. The firm had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. As a group, sell-side analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on the company. HC Wainwright reissued a "buy" rating and issued a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a research report on Saturday. Truist Financial raised their target price on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $37.80.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.